Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations

Arrese, Marco; Barrera, Francisco; Triantafilo, Nicolás; Arab, Juan Pablo

doi:10.1080/17474124.2019.1649981

Cited by 44 publications

(43 citation statements)

References 193 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BFM and VFA are often reported markers in athletes related articles or are used to explore the relationship between insulin resistance and excessive visceral fat accumulation [31,32]. Additionally, elevated data strongly suggests that advanced blood lipids, blood pressure and blood sugar could also be lead to more severe histological changes and poorer clinical outcomes [14,22,33]. Once FL is established, insulin resistance can promote the progression to the more severe state of liver endangerment like non-alcoholic steatohepatitis.…”

Section: Discussionmentioning

confidence: 99%

“…FL is commonly associated obesity, type diabetes, dyslipidemia, and metabolic disorders [8][9][10][11][12]. The relationship between FL and type diabetes is complex and bidirectional and occurs in the context of a wider association between FL and metabolic syndrome [13,14]. In the last decades, an alarming increase in the prevalence of FL has been observed, along with increasing rates of obesity [15].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Comparation of Anthropometric and Metabolic Indices in the Regulation and Prediction of Fatty Liver: a population-based cross-sectional study in China

Xie

Pei

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The association between anthropometric and metabolic indices and fatty liver (FL) remain not fully elucidated. We aimed to determine the role of these anthropometric and metabolic indices on FL prediction and regulation via cross-sectional study, thus providing clues for further research in FL field. Methods: A total of 658 participants aged over 18 years were included in this study. Anthropometric and metabolic indices (including WC, WHR, BMI, BFM, VFA, TG/HDL, AST/ALT, SBP, DBP and FBG) were measured. Difference analyses, logistic and predictive analyses were used to evaluate the association and discrimination ability between these indices and FL. Results: Compared with non-FL, anthropometric and metabolic indices in FL and mild FL people showed a significant increase after adjustment. In the multivariate ranked logistic regression analysis, WC, TG/HDL, AST/ALT and FBG have a strong association with FL (β = 0.03, 0.19, 0.41, -1.89 and 0.28, P<0.05). And AST/ALT showed the lowest predicted power with an AUC of 0.22 among all indices. WC showed to be the best predictors with an AUC of 0.86 in participants.Conclusions: This is a comprehensive profile for FL related indices. These can enhance our understanding of the mechanisms for hepatic on inflammation and fat and is also important for the prevention and treatment of FL.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Comparation of Anthropometric and Metabolic Indices in the Regulation and Prediction of Fatty Liver: a population-based cross-sectional study in China

Xie

Pei

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The epidemiology of NAFLD already parallels the pandemic of obesity. In a disturbed metabolic milieu, both conditions are interrelated with type 2 diabetes (T2D) by common pathophysiological mechanisms-insulin resistance and the progression of compensatory hyperinsulinemia to β-cell demise or defective lipid metabolism [34,35]. This relationship remains complex and bidirectional, and as such, NAFLD may predispose individuals to T2D but not surprisingly, obesity-driven T2D promotes NASH and advanced liver fibrosis, suggesting that end-stage liver disease should be considered an overlooked complication of diabetes.…”

Section: A Round Trip Of Nafld and Diabetes: Two Entities In A Bidirementioning

confidence: 99%

Fat and Sugar—A Dangerous Duet. A Comparative Review on Metabolic Remodeling in Rodent Models of Nonalcoholic Fatty Liver Disease

et al. 2019

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is a common disease in Western society and ranges from steatosis to steatohepatitis to end-stage liver disease such as cirrhosis and hepatocellular carcinoma. The molecular mechanisms that are involved in the progression of steatosis to more severe liver damage in patients are not fully understood. A deeper investigation of NAFLD pathogenesis is possible due to the many different animal models developed recently. In this review, we present a comparative overview of the most common dietary NAFLD rodent models with respect to their metabolic phenotype and morphological manifestation. Moreover, we describe similarities and controversies concerning the effect of NAFLD-inducing diets on mitochondria as well as mitochondria-derived oxidative stress in the progression of NAFLD.

show abstract

“…3,4 NAFLD is the one of the most common liver disorders, affecting approximately 20-40% of the population worldwide, with different burdens according to age, sex, ethnicity, and diagnostic tools. 5,6 The presence of diabetes is closely associated with the severity of NAFLD, progression to NASH, advanced fibrosis, cirrhosis, and even HCC, [7][8][9] independently of liver enzymes. 10,11 Studies on South Korean patients with T2DM who underwent ultrasonography in a university and a private clinic-based diabetes care facility showed 63.3% and 72.7% prevalence of NAFLD, respectively.…”

Section: Introductionmentioning

confidence: 99%

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

Kim

Lee

2020

Clin Mol Hepatol

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder and is associated with various metabolic diseases, including type 2 diabetes mellitus. There are no approved drugs for NAFLD, and the only approved treatment option is weight reduction. As insulin resistance plays an important role in the development of NAFLD, many anti-diabetic drugs have been evaluated for the treatment of NAFLD. Improvement of liver enzymes has been demonstrated by many anti-diabetic drugs, but histological assessment still remains insufficient. Pioglitazone could become the first-line therapy for T2DM patients with NAFLD, based on evidence of histological improvement in patients with biopsy-proven nonalcoholic steatohepatitis (NASH). Liraglutide, another promising alternative, is not yet recommended in patients with NAFLD/NASH due to limited evidence. Therefore, well-designed randomized controlled trials should be performed in the near future to demonstrate if and how anti-diabetic drugs can play a role in the treatment of NAFLD.

show abstract

Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations

Cited by 44 publications

References 193 publications

The Comparation of Anthropometric and Metabolic Indices in the Regulation and Prediction of Fatty Liver: a population-based cross-sectional study in China

The Comparation of Anthropometric and Metabolic Indices in the Regulation and Prediction of Fatty Liver: a population-based cross-sectional study in China

Fat and Sugar—A Dangerous Duet. A Comparative Review on Metabolic Remodeling in Rodent Models of Nonalcoholic Fatty Liver Disease

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

Contact Info

Product

Resources

About